A pilot study investigating the possibility to detect cancer DNA in the blood of cancer patients
Recruiting
- Conditions
- Breast CancerColorectal CancerGliomaNon-small Cell Lung Cancer
- Registration Number
- NL-OMON22021
- Lead Sponsor
- Maastricht University Medical Center (MUMC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer, non-small cell lung cancer and anaplastic glioblastoma, before start of radiation therapy, chemoradiation or chemotherapy.
2. Patients age > 18 years, willing and able to comply with the protocol as judged by the investigator with a signed informed consent
Exclusion Criteria
1. Patients with a history of malignant disease other than the disease under study, with an exception for adequately treated squamous cell carcinoma of the skin, basal cell carcinoma of the skin and in situ cervix carcinoma.
2. Pregnancy
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Demonstrate the presence or absence of ctDNA in patient’s plasma<br>
- Secondary Outcome Measures
Name Time Method Examine if there is a sufficient concentration of ctDNA in the plasma to reliably diagnose cancer and determine the CNV<br><br /><br /><br>Comparison with tumor DNA isolated from the tumor of the patient